지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 1 - 7 (7page)
이용수
초록· 키워드
오류제보하기
Background: While procarbazine, CCNU (lomustine), and vincristine (PCV) has been an alternative chemotherapy option for malignant gliomas, it is worth investigating whether the combination of only procarbazine and CCNU is comparable because vincristine adds toxicity with uncertain benefit. The purpose of this study was to evaluate the feasibility of procarbazine and CCNU chemotherapy for recurrent glioblastoma multiforme (GBM) with O6 -methylguanine-DNA-methyltransferase (MGMT) promoter methylation. Methods: Eight patients with recurrent GBM following concurrent chemoradiotherapy and temozolomide (TMZ) adjuvant therapy were enrolled in this trial; they received no other chemotherapeutic agents or target therapy. They received CCNU (75 mg/m2 ) on day 1 and procarbazine (60 mg/m2 ) through days 11 and 24 every 4 weeks. The median cycle of CCNU and procarbazine was 3.5 (range: 2–6). Results: One patient achieved stable disease. The median progression-free survival (PFS) with procarbazine and CCNU chemotherapy was eight weeks (range: 5–73), and the PFS rates were 25% and 12.5% at 16 and 30 weeks, respectively. The median overall survival (OS) from the initial diagnosis to death was 40 months, and the median OS from the administration of procarbazine and CCNU chemotherapy to death was 9.7 months (95% confidence interval: 6.7–12.7). Serious adverse events were found at six visits, and two cases were considered to be grade 3 toxicities. Conclusion: The efficacy of procarbazine and CCNU chemotherapy is not satisfactory. This study suggests the need to develop other treatment strategies for recurrent and TMZ- refractory GBM. Trial registry at ClinicalTrials.gov, NCT017337346.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Kyritsis AP / 2011 / An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting / Cancer Chemother Pharmacol 67(5):971~983
Stupp R / 2005 / Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma / N Engl J Med 352(10):987~996
Kreisl TN / 2009 / Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma / J Clin Oncol 27(5):740~745
Franceschi E / 2005 / Salvage temozolomide for prior temozolomide responders / Cancer 104(11):2473~2476
Wick W / 2009 / New (alternative) temozolomide regimens for the treatment of glioma / Neuro Oncol 11(1):69~79
Stupp R / 2005 / Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma / N Engl J Med 352(10):987~996
Kreisl TN / 2009 / Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma / J Clin Oncol 27(5):740~745
Franceschi E / 2005 / Salvage temozolomide for prior temozolomide responders / Cancer 104(11):2473~2476
Wick W / 2009 / New (alternative) temozolomide regimens for the treatment of glioma / Neuro Oncol 11(1):69~79
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
Cancer Research and Treatment
2017 .01
-
Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma
대한신경외과학회지
2015 .01
-
Chemotherapy : Is it needed?
대한외과학회 학술대회 초록집
2015 .11
-
The efficacy of chemotherapy in the patients with stage II colon cancer associated with number of high-risk factors
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .12
-
Chemotherapy and targeted therapy
대한외과학회 학술대회 초록집
2016 .11
-
Re-Irradiation and Its Contribution to Good Prognosis in Recurrent Glioblastoma Patients
Brain Tumor Research and Treatment
2020 .01
-
Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage Ⅲ colon cancer
Annals of Surgical Treatment and Research
2015 .08
-
Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer
Journal of Gastric Cancer
2022 .04
-
췌장 및 담도암 환자의 항암 시작, 반응 평가 및 항암 중단 시점
대한췌담도학회지
2020 .01
-
원발성 위장관 림프종의 수술 후 복합 화학요법과 화학요법 단독과의 비교: 단일 기관 연구
고신대학교 의과대학 학술지
2015 .01
-
Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2?Targeted Agent in the Real-World Setting
Cancer Research and Treatment
2021 .01
-
Adjuvant Chemotherapy
대한외과학회 학술대회 초록집
2021 .11
-
Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy
Cancer Research and Treatment
2022 .10
-
The Prognostic Significance of Compliance with Postoperative Adjuvant Chemotherapy in Patients with Stage III Gastric Cancer: an Observational Study
Journal of Gastric Cancer
2018 .03
-
The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study
Cancer Research and Treatment
2023 .01
-
Comparison of the Beneficial Effects of Adjuvant Chemotherapy among Young and Old Aged Breast Cancer Patients
Journal of Breast Disease
2019 .01
-
Quality of life changes during adjuvant chemotherapy in patients with colon cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2016 .06
-
Changes of Cognitive Function and Fatigue following Chemotherapy in Patients with Gastrointestinal Cancer: A Prospective Controlled Study
Asian Oncology Nursing
2019 .09
-
Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence
Asian Pacific journal of cancer prevention : APJCP
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0